Ocugen reported clinical trial progress and financial results, highlighting advancements in gene therapies for retinal diseases and recent FDA alignments. OCU410ST is a therapy for Stargardt disease, ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...

Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted ...

Head and neck cancer trials are frequently derailed before they can deliver answers. A new analysis suggests that the most common reasons are sponsor decisions related to safety or effectiveness and ...

High cholesterol can cause plaque buildup in the arteries. Over time, this can lead to heart attack. One clinical trial aims to lower LDL cholesterol for a lifetime with a single infusion of ...

In the second quarter, the firm began dosing patients in three signal-seeking clinical trials to evaluate BNT327, its VEGF x PD-L1 bispecific, in combination with antibody-drug conjugates as ...

Texas allocates $50 million to UT-led IMPACT partnership for ibogaine clinical trials treating PTSD, addiction, and more.

In 1747, Scottish physician Dr. James Lind conducted an experiment aboard a British naval vessel to find a cure for scurvy, then a devastating cause of illness and death among sailors. He divided 12 ...